Chapter 16. Farnesyltransferase Inhibitors of Microbial Origins in Cancer Therapy

  1. Arsénio M. Fialho3 and
  2. Ananda M. Chakrabarty4
  1. Jingxuan Pan1 and
  2. Sai-Ching Jim Yeung2

Published Online: 18 AUG 2010

DOI: 10.1002/9780470626528.ch16

Emerging Cancer Therapy

Emerging Cancer Therapy

How to Cite

Pan, J. and Jim Yeung, S.-C. (2010) Farnesyltransferase Inhibitors of Microbial Origins in Cancer Therapy, in Emerging Cancer Therapy (eds A. M. Fialho and A. M. Chakrabarty), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi: 10.1002/9780470626528.ch16

Editor Information

  1. 3

    Institute for Biotechnology and Bioengineering (IBB), Center for Biological and Chemical Engineering, Instituto Superior Tecnico, Lisbon, Portugal

  2. 4

    Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, IL, USA

Author Information

  1. 1

    Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, People's Republic of China

  2. 2

    Yeung, Departments of General Internal Medicine, Ambulatory Treatment and Emergency Care, and Endocrine Neoplasia and Hormonal Disorders, The University of Texas, M.D. Anderson Cancer Center, Houston, TX, USA

Publication History

  1. Published Online: 18 AUG 2010
  2. Published Print: 16 JUL 2010

ISBN Information

Print ISBN: 9780470444672

Online ISBN: 9780470626528



  • farnesyltransferase inhibitors - of microbial origins in cancer therapy;
  • manumycin, in vivo activity against human cancer cell lines - in xenograft models;
  • FTIs inducing apoptosis and autophagy in cancer cells - mechanisms involving disruption of farnesylation of farnesylated proteins


This chapter contains sections titled:

  • Ras and Farnesyltransferase Inhibitors (FTIS)

  • Ftis of Microbial Origins

  • Antitumor Activity of Ftis of Microbial Origins

  • Targets of Ftis

  • Future Prospects

  • Acknowledgments

  • References